EGFR

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search
1 regimens on this page
1 variants on this page


All lines of therapy

Erlotinib monotherapy

Regimen

Study Evidence
Hainsworth et al. 2018 (MyPathway) Phase IIa, <20 pts in this arm

Biomarker eligibility criteria

  • Gene: EGFR
  • Alteration: nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
  • Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
  • Biomarker exclusions: EGFR exon 20 mutations

Chemotherapy

Continued indefinitely

References

  1. MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed